ReviewFrontiers in immunology2025
The role of inflammatory factors in the tumor microenvironment of pancreatic cancer.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CTGF: The remodeler of the tumor immune microenvironment (Review).Oncology reports · 2026Review
- Targeting lncRNA-regulated macrophage polarization: a novel therapeutic strategy for pancreatic ductal adenocarcinoma.Journal of physiology and biochemistry · 2026Review
- The Mechanism of MgInternational journal of molecular sciences · 2026Article
- Sodium new houttuyfonate affects tumor angiogenesis by suppressing FGF1 expression and the p38/MAPK signaling pathway in pancreatic cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is an aggressive malignancy with a poor prognosis, and the tumor microenvironment (TME) plays a pivotal role in its initiation, progression, and response to treatment. Recent studies have highlighted the critical involvement of inflammatory factors in shaping and sustaining the PC microenvironment. Chronic inflammation is a hallmark of this cancer, with inflammatory molecules such as cytokines, chemokines, proteases, and other immune-modulatory factors driving tumor cell proliferation, metastasis, and resistance to therapy. These inflammatory factors exert their effects by modulating immune cell infiltration, extracellular matrix (ECM) remodeling, and angiogenesis. This review provides an overview of the diverse roles of inflammatory factors in the PC TME and explores their potential as therapeutic targets. It offers new perspectives for developing novel immunotherapies and inflammation-modulating strategies to improve the treatment of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.